Skip Navigation


Rheumatology Advance Access originally published online on October 12, 2009
Rheumatology 2009 48(11):1335-1336; doi:10.1093/rheumatology/kep334
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
48/11/1335    most recent
kep334v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Isenberg, D.
Right arrow Articles by Müeller-Ladner, U.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Isenberg, D.
Right arrow Articles by Müeller-Ladner, U.
Related Collections
Right arrow Pharmacology
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Editorial

Registries in rheumatological and musculoskeletal conditions—call for papers

David Isenberg1, Roy Fleischmann2 and Ulf Müeller-Ladner3

1UCL Division of Medicine, Centre for Rheumatology, University College London, London, UK, 2University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX, USA and 3Department of Rheumatology and Clinical Immunology, Justus-Liebig University Giessen, Kerckhoff-Clinic, Bad Nauheim, Germany.

Correspondence to: David Isenberg, UCL Division of Medicine, Centre for Rheumatology, University College London, Windeyer Building, 46 Cleveland Street, London W1T 4JF, UK. E-mail: d.isenberg@ucl.ac.uk

The first 10% of the full text of this article appears below.

The outlook for patients with various inflammatory arthropathies, notably RA, PsA and AS, has been altered substantially in the past decade by the introduction of biologic agents, in particular those which block TNF-{alpha} and also by agents that either block co-stimulation or affect CD20 B cells. Although double-blind control trials involving thousands of patients have demonstrated the effectiveness of these drugs, such as etancercept [1], infliximab [2], adalimumab [3] and newer drugs such as certolizumab golimumab, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?